Navigation Links
Drug Combo Might Fight Aggressive Breast Cancer More Safely
Date:10/6/2011

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Oct. 5 (HealthDay News) -- Treating women with an aggressive form of early stage breast cancer using Herceptin and chemotherapy, while not turning to a third type of drug known as an anthracycline, improves survival while posing less danger to the heart, researchers report.

They tested three different regimens, one of which did not include any anthracyclines. When Herceptin is given with doxorubicin (Adriamycin), an anthracycline, toxic cardiac effects have been seen.

"What the study shows is you have comparable effectiveness in a Herceptin-based regimen when you don't use the anthracyclines," said Dr. Dennis Slamon, director of clinical and translational research at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles. Earlier research of his led to the development of Herceptin (trastuzumab).

He contends that the new regimen should be the new standard of care, but one expert who wrote an accompanying commentary disagreed.

The new study is published in the Oct. 6 issue of the New England Journal of Medicine.

Slamon and his colleagues from the Breast Cancer International Research Group tested one of three different treatments in 3,222 women who had HER2-positive early-stage breast cancer. This breast cancer is more aggressive and is linked with a worse outlook and shorter survival times.

One group got a regimen called ACT-- the standard therapy of doxorubicin (Adriamycin) and paraplatin (Carboplatin) followed by docetaxel (Taxotere). A second group got that same standard regimen plus a year of Herceptin -- called ACTH. The third group got the anthracycline-free regimen, called TCH -- doxetaxel (Taxotere) and paraplatin (Carboplatin) with a year of Herceptin.

Herceptin targets HER2, a protein known as human epidermal growth factor receptor 2. In about one of five breast cancers, a gene mutation leads to excess production of HER2 in the cancer cells.

The researchers evaluated disease-free survival and overall survival at five years. The addition of the one year of Herceptin improved both disease-free and overall survival. The disease-free survival rates at five years were 75 percent in the ACT group, 84 percent in the ACTH group and 81 percent in the TCH group.

Overall survival was 87 percent for the ACT group, 92 percent for the ACTH and 91 percent in the TCH group.

However, the rates of congestive heart failure and other cardiac problems were higher in the ACTH group than in the TCH group. Twenty-one of those on ACTH had congestive heart failure, compared with four in the TCH group.

There were fewer reports of side effects such as joint pain and vomiting with the TCH group compared with the ACTH group, Slamon found. "And you get comparable effects," he noted.

Sanofi-Aventis and Genentech (which makes Herceptin) funded the study; Slamon reports receiving honoraria and reimbursement for travel expenses from both companies.

The latest report echoes findings from several previous ones, Slamon said. Doctors have been using the TCH regimen in women at risk for cardiac problems; it is approved by the U.S. Food and Drug Administration. "We're saying it should be used for everybody," Slamon said. "We are saying we think it is the standard of care, with comparable effects, and you lose all the anthracycline toxicity."

However, Dr. Daniel F. Hayes, clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center in Ann Arbor, disagreed.

"I think TCH is a standard of care, it's not the standard of care," he said.

"Herceptin itself can cause heart failure," Hayes said. In the study, there were fewer cases of it in those who got Herceptin without anthracyclines, but it did still occur.

He suggests a risk-adapted approach, in which a doctor would decide which regimen to use based on a woman's cardiac risk.

Oncologists have had the option of anthracycline-free regimens for a number of years, Hayes noted, although the new study does add some more solid numbers to the outcomes for each regimen.

More information

To learn more about breast cancer, visit the American Cancer Society.

SOURCES: Dennis Slamon, M.D., director, clinical and translational research, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Daniel F. Hayes, M.D., clinical director, breast oncology program, University of Michigan Comprehensive Cancer Center, Ann Arbor; Oct. 6, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. For Some Prostate Cancer Patients, Combo Treatment Improves Survival
2. New Combo Therapy May Prevent TB, Save Lives in People With HIV
3. Vitamin D, Calcium Combo May Halve Melanoma Risk in Some Women
4. Energy Drink-Vodka Combo Nearly Kills Teen
5. Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study
6. Combo of Paxil, Pravachol May Raise Blood Sugar
7. Chemo Combo May Help Stave Off Pancreatic Cancer Death
8. Alcohol-Energy Drink Combo Riskier Than Booze Alone, Study Says
9. Low-Intensity Exercise, Drug Combo Can Help Parkinsons Patients, Studies Show
10. Diet-Exercise Combo Seems to Work Best for Obese Seniors
11. Risks May Outweigh Benefits for Blood Pressure Drug Combo
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Combo Might Fight Aggressive Breast Cancer More Safely
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: